What are Agilon Health's total assets?

Agilon Health (AGL) holds $1.5B in total assets, down 22.1% year over year.

How much debt does Agilon Health have?

Agilon Health carries $33.4M in total debt against $181.4M of shareholders' equity, a debt-to-equity ratio of 0.18.

How much cash does Agilon Health have?

Agilon Health holds $211.6M in cash and equivalents.

Can Agilon Health cover its short-term obligations?

Its current ratio is 1.04 — current assets exceed current liabilities.

Where does Agilon Health's balance sheet data come from?

Every line is extracted from Agilon Health's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Agilon Health AGL Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$211.57M+21.8%	$173.71M+1.2%	$171.68M+0.2%	$171.42M+23.7%	$138.62M-28.5%
Accounts receivable, net	$899.75M+33.5%	$673.79M-28.9%	$947.16M-9.6%	$1.05B-15.5%	$1.24B+21.9%
Prepaid expenses and other current assets	$414.71M+22.5%	$338.63M+43.5%	$236M+17.5%	$200.84M+24.5%	$161.36M+1.6%
Trading assets	——	——	——	——	——
Total current assets	$1.32B+20.5%	$1.1B-18.0%	$1.34B-7.9%	$1.45B-12.0%	$1.65B+13.2%
Property and equipment, net	$24.89M-2.1%	$25.42M-2.8%	$26.15M-4.6%	$27.41M-2.4%	$28.09M-0.3%
Operating lease right-of-use assets	$5.24M+48.0%	$3.54M-10.0%	$3.94M-55.5%	$8.84M-9.3%	$9.74M+10.9%
Intangible assets, net	$62.45M-5.0%	$65.73M-12.7%	$75.25M+14.7%	$65.6M-3.8%	$68.19M-6.3%
Other non-current assets	$3.54M-8.9%	$3.89M-74.2%	$15.08M+1.1%	$14.92M-1.3%	$15.11M-1.8%
Equity method investments	$72.15M+20.7%	$59.79M-33.9%	$90.47M+16.1%	$77.91M+6.7%	$73.04M+18.3%
Available-for-sale securities	$0—	$0—	$0—	$0—	$0—
Total assets	$1.5B+18.4%	$1.27B-20.4%	$1.6B-6.8%	$1.71B-11.4%	$1.93B+11.5%
Accounts payable	$202.48M+58.8%	$127.48M-12.4%	$145.52M-15.3%	$171.89M-24.2%	$226.69M+2.9%
Current portion of long-term debt	$14.75M-23.3%	$19.24M-45.0%	$34.97M—	——	——
Total current liabilities	$1.27B+18.2%	$1.08B-13.2%	$1.24B-0.7%	$1.25B-9.1%	$1.37B+19.3%
Long-term debt	$15.28M-3.0%	$15.75M—	$0—	$0—	$0-100%
Operating lease liabilities, non-current	$3.38M+84.7%	$1.83M-15.2%	$2.16M-66.5%	$6.43M-9.4%	$7.1M+7.5%
Other non-current liabilities	$35.9M-31.4%	$52.32M+4.0%	$50.29M-8.4%	$54.88M-5.2%	$57.91M-23.9%
Reserve for insurance claims	$1.06B+13.5%	$929.77M-12.2%	$1.06B+1.6%	$1.04B-6.4%	$1.11B+19.5%
Total liabilities	$1.32B+15.6%	$1.14B-11.3%	$1.29B-1.1%	$1.3B-9.0%	$1.43B+13.4%
Common stock	2B0.0%	2B0.0%	2B0.0%	2B0.0%	2B+48,420%
Additional paid-in capital	$2.11B+0.3%	$2.1B+0.6%	$2.09B+0.3%	$2.08B+0.6%	$2.07B+0.8%
Retained earnings	-$1.93B+2.5%	-$1.98B-10.6%	-$1.79B-6.6%	-$1.68B-6.6%	-$1.57B+0.8%
Accumulated other comprehensive income (loss)	$479K-47.7%	$916K+4.1%	$880K+11.8%	$787K+44.9%	$543K+717%
Total stockholders' equity	$181.43M+43.2%	$126.73M-58.6%	$306.08M-25.2%	$408.93M-18.3%	$500.25M+6.2%
Total liabilities and stockholders' equity	$1.5B+18.4%	$1.27B-20.4%	$1.6B-6.8%	$1.71B-11.4%	$1.93B+11.5%
Available-for-Sale Debt Securities	$91.42M-18.0%	$111.43M-19.9%	$139.17M-10.6%	$155.59M-32.4%	$230.14M+8.7%
Available-for-Sale Debt Securities - Amortized Cost	$91.07M-17.7%	$110.61M-20.1%	$138.4M-10.7%	$154.91M-32.6%	$229.67M+8.4%
Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)	——	——	——	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	——	——	——	$16.98M-79.3%	$81.99M-26.7%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	——	——	$16.98M-79.3%	$81.99M-26.7%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	$26.36M-25.6%	$35.43M+40.1%
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	——	——	——	$26.36M-25.6%	$35.43M+40.1%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	——	——	$16.98M-79.3%	$81.99M-26.7%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	——	$26.36M-25.6%	$35.43M+40.1%
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$211.57M+21.8%	$173.71M+1.2%	$171.68M+0.2%	$171.42M+23.7%	$138.62M-28.5%
Debt securities - current	$91.42M-18.0%	$111.43M-19.9%	$139.17M-10.6%	$155.59M-32.4%	$230.14M+8.7%
Restricted Cash Equivalents Current	$71.58M—	$0—	$0—	$0-100%	$1.68M-70.1%
Deferred Tax Assets and Other Non-Current Assets	$96.43M+15.6%	$83.45M-37.1%	$132.68M-7.3%	$143.1M-11.5%	$161.73M+7.0%
Net Investment in Lease	$5.24M+48.0%	$3.54M-10.0%	$3.94M-55.5%	$8.84M-9.3%	$9.74M+10.9%
Other intangible assets—net	$62.45M-5.0%	$65.73M-12.7%	$75.25M+14.7%	$65.6M-3.8%	$68.19M-6.3%
Operating lease right-of-use assets	$5.24M+48.0%	$3.54M-10.0%	$3.94M-55.5%	$8.84M-9.3%	$9.74M+10.9%
Other non-current assets	$96.43M+15.6%	$83.45M-37.1%	$132.68M-7.3%	$143.1M-11.5%	$161.73M+7.0%
Operating Lease Right-of-Use Assets in Other Assets	$5.24M+48.0%	$3.54M-10.0%	$3.94M-55.5%	$8.84M-9.3%	$9.74M+10.9%
Software and Technology Licenses, Net	$96.43M+15.6%	$83.45M-37.1%	$132.68M-7.3%	$143.1M-11.5%	$161.73M+7.0%
Accrued Contingent Liabilities	$16M-54.3%	$35M0.0%	$35M0.0%	$35M0.0%	$35M-28.6%
Accounts payable and other current liabilities (Note 11)	$202.48M+58.8%	$127.48M-12.4%	$145.52M-15.3%	$171.89M-24.2%	$226.69M+2.9%
Liability for Claims and Claims Adjustment Expense	$1.06B+13.5%	$929.77M-12.2%	$1.06B+1.6%	$1.04B-6.4%	$1.11B+19.5%
Non-current Loss Contingency Accrual	$16M-54.3%	$35M0.0%	$35M0.0%	$35M0.0%	$35M-28.6%
Total debt	$33.4M-9.3%	$36.82M-0.8%	$37.12M-10.3%	$41.37M-1.5%	$42.02M-4.4%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	——	——	$6K-93.8%	$97K-69.0%
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	16.6M+0.1%	16.6M-96.0%	414.6M+0.1%	414.3M+0.3%	413M+0.2%
Additional paid-in capital	$2.11B+0.3%	$2.1B+0.6%	$2.09B+0.3%	$2.08B+0.6%	$2.07B+0.8%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$166K0.0%	$166K-96.0%	$4.15M+0.1%	$4.14M+0.3%	$4.13M+0.2%
Unrealized Gains on Investments	$352K-57.0%	$819K+5.0%	$780K+5.3%	$741K+18.0%	$628K+128%
Unrealized Losses on Investments (Before Tax)	$0-100%	$1K-90.9%	$11K-82.0%	$61K-61.4%	$158K-62.1%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0-100%	$1K-90.9%	$11K-82.0%	$61K-61.4%	$158K-62.1%
Gross Unrealized Gains	$352K-57.0%	$819K+5.0%	$780K+5.3%	$741K+18.0%	$628K+128%
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——	——
Cash and cash equivalents, end of period	$211.57M+21.8%	$173.71M+1.2%	$171.68M+0.2%	$171.42M+23.7%	$138.62M-28.5%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$2B0.0%	$2B0.0%	$2B0.0%	$2B0.0%	$2B0.0%
Common stock, shares issued (in shares)	$16.61M+0.1%	$16.59M-96.0%	$414.57M+0.1%	$414.28M+0.3%	$413.02M+0.2%
Common Stock, Shares, Outstanding	$16.61M+0.1%	$16.59M-96.0%	$414.57M+0.1%	$414.28M+0.3%	$413.02M+0.2%
2028	——	——	——	——	——
Available-for-sale securities, allowance for credit loss	$0—	$0—	$0—	$0—	$0—
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$91.07M-17.7%	$110.61M-20.1%	$138.4M-10.7%	$154.91M-32.6%	$229.67M+8.4%
2027	——	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	——	——	——	$6K-93.8%	$97K-69.0%
Less than 12 months	——	——	——	$26.36M-25.6%	$35.43M+40.1%
12 months or more	——	——	——	$16.98M-79.3%	$81.99M-26.7%
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	——	——	——	$55K-9.8%	$61K-41.3%
Estimated Fair Value	$91.42M-18.0%	$111.43M-19.9%	$139.17M-10.6%	$155.59M-32.4%	$230.14M+8.7%
2028	——	——	——	——	——
2027	——	——	——	——	——
Equity method investments (Note 11)	$72.15M+20.7%	$59.79M-33.9%	$90.47M+16.1%	$77.91M+6.7%	$73.04M+18.3%
Equity Method Liabilities	$12.78M+5.1%	$12.16M+24.2%	$9.79M-5.5%	$10.36M-5.0%	$10.9M-11.3%
Equity method liabilities – CMS ACO Models	$12.78M+5.1%	$12.16M+24.2%	$9.79M-5.5%	$10.36M-5.0%	$10.9M-11.3%
Health plan deposits	$2.08M0.0%	$2.08M0.0%	$2.08M+1.3%	$2.05M0.0%	$2.05M0.0%
Related payables associated with retained liability	$39.8M+15.4%	$34.5M+17.7%	$29.3M+2.8%	$28.5M+80.4%	$15.8M+18.8%
Liability For Claims And Claims Adjustment Expense, Including Amounts Recoverable	$1.02B+13.4%	$895.28M-13.1%	$1.03B+1.6%	$1.01B-7.6%	$1.1B+19.5%
Loans to physician partners	$13.43M-5.2%	$14.16M-33.0%	$21.12M-46.4%	$39.38M-36.3%	$61.79M-2.2%
Number of geographies	——	——	——	——	——
Number of medicare advantage members enrolled with private health plans	——	——	——	——	——
Other	$3.74M+12.2%	$3.34M-0.2%	$3.35M+8.1%	$3.1M-37.0%	$4.91M-40.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Agilon Health.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Agilon Health's total assets?: Agilon Health (AGL) holds $1.5B in total assets, down 22.1% year over year.
How much debt does Agilon Health have?: Agilon Health carries $33.4M in total debt against $181.4M of shareholders' equity, a debt-to-equity ratio of 0.18.
How much cash does Agilon Health have?: Agilon Health holds $211.6M in cash and equivalents.
Can Agilon Health cover its short-term obligations?: Its current ratio is 1.04 — current assets exceed current liabilities.
Where does Agilon Health's balance sheet data come from?: Every line is extracted from Agilon Health's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.